PLX4032, a selective BRAF <sup>V600E</sup> kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF <sup>WT</sup> melanoma cells
Ruth Halaban(Yale University), Mario Sznol(Yale University)
Cited by 322
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753